NeoStem, Inc. Appoints Vice President of Sales and Marketing

NEW YORK, Oct. 5 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS),
which is pioneering the pre-disease collection, processing and long-term
storage of adult stem cells for future medical need, announced today it has
appointed Teresa Lepore, as the Company's Vice President, Sales and Marketing.

Teresa Lepore began serving as the Company's Vice President, Sales and
Marketing on October 1, 2009. Since March 2005, she served as a Senior Vice
President for PinnacleCare, a company engaged in Health Advisory Services.
Teresa was responsible for establishing PinnacleCare's Northeast offices in
early 2005. Teresa initiated member services, network development, business
development as well as staff recruitment and development. Teresa has a
diverse background in medical advisory services, disease management program
development, community development, fundraising, marketing and non-profit
administration. Prior to joining PinnacleCare, from March 2002 through June
2004 she was a Health Education Specialist for WellPoint Health Networks, a
company engaged in Health Benefits where she designed disease management
programs.

Teresa spent fifteen years in Non-Profit administration before moving into
Health Information and Advisory Services. Her non profit background began in
crisis intervention programs helping to establish shelters and programs
advocating for victims of domestic violence, including Child and Elder abuse.
Her responsibilities included the training and supervision of staff grant
writing and general fundraising. In addition to direct client service
organizations Teresa served as a Resource and Capitalization Coordinator for
Common Wealth, Inc., where she was responsible for resource development
activities, grant writing, fundraising, and marketing. She provided training
and consulting services to community and grassroots groups in community
organizing, grant writing, marketing, project planning and resource
development. Teresa received a Bachelor of Science from Youngstown State
University in 1997.

Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer, said, "We are
extremely pleased to add Ms. Lepore to our management team at NeoStem. Her
extensive experience and success in the high end concierge medical services
industry will be critical for the roll out of our collection, processing and
storage business in the US. Additionally, her not for profit background will
allow us to focus more on assisting the Stem-for-Life Foundation grow to
support autologous stem cell research and assist first responders in having
their own stem cells collected."

About NeoStem, Inc.
NeoStem is developing a network of adult stem cell collection centers that are
focused on enabling people to donate and store their own (autologous) stem
cells when they are young and healthy for their personal use in times of
future medical need. The Company has also entered into research and
development through the acquisition of a worldwide exclusive license to
technology to identify and isolate VSELs (very small embryonic-like stem
cells), which have been shown to have several physical characteristics that
are generally found in embryonic stem cells and is pursuing other technologies
to advance its position in the field of stem cell tissue regeneration. For
more information, please visit: www.neostem.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of this
press release, and involve certain risks and uncertainties. The Company's
actual results could differ materially from those anticipated in these
forward-looking statements as a result of various factors. Factors that could
cause future results to materially differ from the recent results or those
projected in forward-looking statements include the "Risk Factors" described
in the Company's Annual Report on Form 10-K for the fiscal year ended December
31, 2008 and the Company's other periodic filings with the Securities and
Exchange Commission. The Company's further development is highly dependent on
future medical and research developments and market acceptance, which is
outside its control.

CONTACT:
NeoStem, Inc.
Robin Smith, Chief Executive Officer
T: 212-584-4180
E: rsmith@neostem.com

SOURCE NeoStem, Inc.

NeoStem, Inc., Robin Smith, Chief Executive Officer, +1-212-584-4180,
rsmith@neostem.com